Navigation Links
Stemedica Enters into Stem Cell Licensing Agreement with Kalbe Farma
Date:4/25/2013

San Diego, CA (PRWEB) April 25, 2013

Stemedica Asia PTE, LTD, a wholly owned subsidiary of Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced that the Company has entered into a definitive licensing agreement with the Stem Cell and Cancer Institute, a division of PT Kalbe Farma Tbk. (Kalbe). Under the terms of the Agreement Kalbe shall be the exclusive licensor of Stemedica’s ischemic tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical trials in Indonesia, Philippines and Thailand. The Agreement also provides Kalbe with first rights of refusal for additional countries including Singapore, Malaysia, Vietnam, Brunei, Cambodia, Laos and Myanmar. Kalbe’s Stem Cell and Cancer Institute shall be responsible for organizing and funding clinical trials in Southeast Asia.

Headquartered in Central Jakarta, Indonesia, Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with close to US $6.5 billion in market capitalization as of Q1 2013. Established in 1966, Kalbe has expanded by strategic acquisitions of companies involved in prescription and over-the-counter pharmaceuticals, energy drinks and nutritional products. Kalbe’s Prescription Pharmaceutical Division features a complete product range including the manufacture of generics and licensed drugs. Pharma Metric Labs, a Kalbe company, is an independent Contract Research Organization (CRO) providing global studies in oncology, monoclonal antibodies and stem cells. Kalbe’s packaging and distribution capabilities allow the company to reach over one million outlets with their brands.

Kalbe’s Stem Cell and Cancer Institute was established in 2006 as part of Kalbe’s founder Dr. Boenjamin Setiawan’s belief that stem cells and regenerative medicine represent the future of medicine. According to Dr. Setiawan, “Our scientists and researchers have thoroughly evaluated worldwide stem cell manufacturers. We have chosen to license Stemedica products based upon the quality of their cGMP manufacturing and the unique attributes of their ischemia tolerant stem cells. Their ability to scale production to treat hundreds of thousands of patients from a single tissue donation is in keeping with our objective as a pharmaceutical company: to bring a safe, effective, off-the-shelf solution to millions of people in Southeast Asia suffering from disease.”

Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica noted, “We are honored to be associated with a company of Kalbe’s caliber; a company that strictly adheres to the ethical and regulatory guidelines in medicine.”

Addressing the significance of the collaboration, Maynard Howe, PhD, Stemedica’s Vice-Chairman and Chief Executive Officer noted, “Our agreement with Kalbe is in keeping with our corporate strategy of partnering with global and regional pharmaceutical companies that are committed to licensing our multiple stem cell products for use in approved clinical trials. We are extremely pleased to have a strong partner such as Kalbe for Southeast Asia.”

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and myocardial infarct. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

About PT. Kalbe Farma Tbk.
PT Kalbe Farma Tbk. (“Kalbe”) is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has a broad and strong portfolio of brands in prescription pharmaceuticals (Cefspan, Brainact, Broadced, etc), OTC pharmaceuticals (Woods, Promag, Mixagrip, Komix, etc), ready-to-drink products (Hydro Coco, Extra Joss, Nitros) and nutritional products (Milna, Prenagen, Diabetasol, etc), complemented with a robust distribution arm covering much of the Indonesian archipelago. Since 1991, Kalbe’s shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).

For more information please contact Dave McGuigan at dmcguigan (at) stemedica (dot) com.

Read the full story at http://www.prweb.com/releases/stemedica-stem-cells/kalbe-asia-licensing/prweb10613321.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
2. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
3. Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
4. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
5. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
6. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
7. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
8. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
9. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
10. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
11. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- - New FDA action date of July ... date of July 22, 2016   --> ... 2016   - Lifitegrast has the potential ... the treatment of signs and symptoms of dry eye disease in ... be the only product approved in the U.S. in the past decade indicated for the ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and triple quad LC-MS, host live demos and poster sessions, and present on ... exhibition. The conference takes place March 6 to 10 at the Georgia World ...
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 ... the "Company"), a biopharmaceutical company focused on the development and ... present at the 18 th Annual BIO CEO ... 10:00 a.m. EST in New York, NY ... CEO, will provide an update on the ongoing clinical trial ...
Breaking Biology Technology:
(Date:2/3/2016)... DUBLIN , Feb. 3, 2016 /PRNewswire/ ... announced the addition of the "Emotion ... NLP, Machine Learning, and Others), Software Tools ... Application Areas, End Users,and Regions - Global ... offering. --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
Breaking Biology News(10 mins):